Latest Shareholder Approval News

Morella Corporation has locked in A$1.4 million in convertible note funding from key shareholders and directors, strengthening its financial position to advance critical minerals exploration and acquisitions.

Aurumin Limited has obtained ASIC approval to extend its 2025 AGM deadline, aligning with the proposed acquisition by Brightstar Resources. This move sets the stage for a significant ownership change pending shareholder approval.

Chalice Mining is progressing its Gonneville Project Pre-Feasibility Study on schedule for November 2025 completion, fully funded and targeting a Final Investment Decision by late 2027 as palladium prices hit a two-year high.

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.

United States Antimony Corporation has proposed acquiring Larvotto Resources in a deal that could create one of the largest antimony producers outside China, offering Larvotto shareholders a significant premium.

Southern Palladium has raised A$20 million through a strategic share placement to accelerate its Bengwenyama PGM project, positioning the company for key milestones including a Final Investment Decision in 2026.

Jindalee Lithium has launched an options offer linked to its recent Share Purchase Plan and placements, aiming to incentivize shareholders and raise capital for its lithium development projects. The options carry an exercise price of $0.825 and expire in late 2028.

Jindalee Lithium has successfully raised $8 million through a private placement, complemented by a $1 million Share Purchase Plan, to advance its McDermitt Lithium Project and a strategic US SPAC transaction.

European Lithium Limited has launched a replacement options offer for holders of 205 million expiring options, with directors committing to fully participate and underwrite the offer pending shareholder approval at the upcoming AGM.

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Australian Strategic Materials secures A$50.8 million via share placement to fund Korean plant expansion and advance US metals project, while navigating complex supply chain and funding risks.